Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2289 +0.0040 (+1.78%)
Streaming Delayed Price Updated: 9:44 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the BIO International Convention 2025
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third... 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presenting at the ThymUS 2025 Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces 2025 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
From D. Boral Capital
Via GlobeNewswire
News headline image
FibroBiologics Announces $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.